Subscription Center
Jun 30, 2009 12:54 PM | 3
How much are cancer drugs worth that may only prolong a patient’s life by a few weeks? It’s a pressing question given the rising cost of medicines, and one that a pair of National Institutes of Health researchers is urging cancer specialists to tackle now.
NIH’s Tito Fojo, who works on experimental cancer therapies, and Christine Grady, a bioethicist, call upon oncologists and the government to figure out when a costly cancer drug is worth prescribing and when it is not, saying, “We cannot ignore the cumulative costs of the tests and treatments we recommend and prescribe.”
The pair’s recent commentary in the Journal of the National Cancer Institute takes a look at drugs like Erbitux, a supplemental drug for the treatment of non-small cell lung cancer. Erbitux costs about $80,000 for 18 weeks of treatment, they write, while only prolonging life by an average of 1.2 months. The drug also carries side effects.
So is the money spent on Erbitux worthwhile? The paper outlines potential standards for oncologists to apply in assessing the value of a drug before writing a prescription.
Fojo and Grady have company in raising the cost issue. Colorectal cancer specialist Leonard Saltz, from Memorial Sloan-Kettering Cancer Center, elaborates on the problem in a recent interview with CurrentMedicine.TV. The cost of new treatments has snuck up on practitioners but now needs to be dealt with head-on, he says.
“The problem is that none of the [new] drugs do what they set out to do, which is replace that which came before them,” Saltz explains. “They get added to the mix,” he says, and drive up costs without necessarily showing an adequate benefit.
Image courtesy of fluxfoto via iStockphoto
Tags:
cancer,
cost,
cancer drug,
Erbitux
More News Blog:
Next: Stuck Mars rover passing its time as an observatory
Previous: The secret right under our (bottle)noses: What dolphins can teach us about hydrodynamics
See what we're tweeting about
Deadline: Jul 15 2013
Reward: $5,000 USD
SciBX: Science-Business eXchange, a joint publication from the makers
Deadline: Aug 31 2013
Reward: $100,000 USD
The Geoffrey Beene Foundation Alzheimer’s Initiative (GBFAI) is launching the 2013 Geoffrey Beene Global NeuroDiscovery Challenge whose
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
3 Comments
Add CommentWho would or should be in a position to tell someone it is not woth $80,000 to extend one's life by 1.2 months; specially if the patient has $100,000 in the bank? The patient's potential heirs, the government?
Reply | Report Abuse | Link to thisWho are these people to decide if it cost beneficial to prolong a person's life, whether it be for a month or longer in other cases! Everything is about money, money, money... start thinking about people for a change!
Reply | Report Abuse | Link to thisCan someone please help me with the cost of cancer treatment for both direct and indirect cost? I am most interested in Colorectal and Breast Cost.
Reply | Report Abuse | Link to this